'Data mining' and 'p-value hacking': Cel-Sci CEO tries to spin cancer trial failure into a win

'Data mining' and 'p-value hacking': Cel-Sci CEO tries to spin cancer trial failure into a win

Source: 
Fierce Biotech
snippet: 

Cel-Sci CEO Geert Kersten begged investors in 2018 to hold on until phase 3 data could prove the struggling biotech’s cancer drug worked. Fast forward to 2021: The results are in, and they are unlikely to inspire the rally needed to save the company.